ArticleVeterinary dermatology2025
An open-label pilot study on an adsorbent mousse containing adelmidrol in client-owned cats with feline atopic skin syndrome and associated seborrhoea.
Article in Veterinary dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBesides pruritus and skin lesions, cats with feline atopic skin syndrome (FASS) may have seborrhoea. HYPOTHESIS/
objectivesThe aim of this pilot study was to investigate whether an adsorbent mousse containing tapioca starch, adelmidrol and a nonpharmacological antimicrobial complex could decrease FASS-associated seborrhoea in cats. ANIMALS: Seven client-owned cats with FASS were included based on the presence of seborrhoea and pruritus (>4 cm on the validated feline pruritus Visual Analog Scale [VAScat]), regardless of the concomitant administration of antiallergic drugs, provided that they were used for ≥1 month before study entry and maintained unchanged. MATERIALS AND
methodsCats were evaluated weekly by owners and every other week by veterinary surgeons for 2 (optionally 4) weeks using a four-item skin seborrhoeic index (SSI). The VAScat and the scoring feline allergic dermatitis (SCORFAD) index also were used to assess pruritus and skin lesion severity, respectively. The Wilcoxon signed-rank test was used for pre- versus post-treatment comparisons.
resultsAt the end of Week 2, the mean score value for SSI was significantly decreased (p = 0.016). At the same time point, the mean severity of pruritus and the mean SCORFAD index value had also decreased (p = 0.016). Moreover, 86% of the investigators were 'satisfied' or 'very satisfied' with the tested mousse. Four cats continued the study up to Week 4 and showed a further, albeit nonsignificant, decrease in all evaluated scores. CONCLUSIONS AND CLINICAL RELEVANCE: These preliminary findings have promising implications for clinical practice in cats with FASS-associated seborrhoea and are worth further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.